Efektivitas Penggunaan Empagliflozin terhadap Nilai HbA1c pada Pasien Diabetes Melitus Tipe 2
Tesalonika Rawung,
Jimmy Posangi,
Edward Nangoy
Abstract:Type 2 diabetes mellitus (T2DM) is the most common type of diabetes today. Lifestyle changes are one of the causes of DM problems. Patients with T2DM are usually treated with oral hypoglycemic drugs. The sodium glucose cotransporter 2 (SGLT-2) group is a type of oral hypoglycemic drug groups that plays a role in reducing HbA1c level. Empagliflozin is a drug included in the SGLT-2 group. Previous clinical trials showed that empagliflozin could lead to a reduction in HbA1c level. This study aimed to determine th… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.